| scholarly article | Q13442814 |
| P50 | author | Alessandra Minelli | Q61090039 |
| P2093 | author name string | Massimo Gennarelli | |
| Cesare Turrina | |||
| Paolo Valsecchi | |||
| Antonio Vita | |||
| Giacomo Deste | |||
| Stefano Barlati | |||
| Edoardo Giacopuzzi | |||
| P2860 | cites work | How precise is precision medicine for schizophrenia? | Q87506791 |
| Neuroimaging Studies of Cognitive Function in Schizophrenia | Q91477386 | ||
| Biological insights from 108 schizophrenia-associated genetic loci | Q24561833 | ||
| Functional magnetic resonance imaging in schizophrenia | Q24635437 | ||
| A review of MRI findings in schizophrenia | Q24657354 | ||
| Brain Structural Effects of Antipsychotic Treatment in Schizophrenia: A Systematic Review | Q26786253 | ||
| Pharmacogenetics and outcome with antipsychotic drugs | Q26852807 | ||
| Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia | Q27026382 | ||
| Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function | Q27704016 | ||
| Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics | Q28079065 | ||
| Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1 | Q28262025 | ||
| Comment on "Genetically determined differences in learning from errors" | Q28286934 | ||
| Regulation of neurotransmitter release by metabotropic glutamate receptors | Q28506056 | ||
| PGC-1α negatively regulates extrasynaptic NMDAR activity and excitotoxicity | Q28575407 | ||
| Molecular diversity of glutamate receptors and implications for brain function | Q28611078 | ||
| Genome-wide association study of treatment refractory schizophrenia in Han Chinese | Q28943538 | ||
| Facial emotion processing in schizophrenia: a meta-analysis of functional neuroimaging data | Q30474410 | ||
| The relationship of structural brain imaging parameters to antipsychotic treatment response: a review | Q30839573 | ||
| Very poor outcome schizophrenia: clinical and neuroimaging aspects | Q31120582 | ||
| The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. | Q31657420 | ||
| Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia | Q31861838 | ||
| The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements | Q33566124 | ||
| A glutamatergic deficiency model of schizophrenia | Q33598404 | ||
| Effects of Antipsychotic Administration on Brain Glutamate in Schizophrenia: A Systematic Review of Longitudinal 1H-MRS Studies | Q33611412 | ||
| Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study | Q33754429 | ||
| Pharmacogenetics of antipsychotics | Q33836837 | ||
| Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies | Q33860665 | ||
| Meta-analysis of regional brain volumes in schizophrenia | Q33885349 | ||
| Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia | Q33924576 | ||
| Practice guideline for the treatment of patients with schizophrenia, second edition. | Q33976372 | ||
| Remission in schizophrenia: proposed criteria and rationale for consensus | Q33985442 | ||
| Caudate and putamen volumes in good and poor outcome patients with schizophrenia | Q48188134 | ||
| Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients | Q48280225 | ||
| Structural disconnectivity in schizophrenia: a diffusion tensor magnetic resonance imaging study | Q48320922 | ||
| Dopamine synthesis capacity in patients with treatment-resistant schizophrenia | Q48350915 | ||
| Effects of endurance training on brain structures in chronic schizophrenia patients and healthy controls | Q48359013 | ||
| Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible? | Q48364681 | ||
| Association between regional brain volumes and clozapine response in schizophrenia | Q48449468 | ||
| Ventricular enlargement in poor-outcome schizophrenia | Q48457497 | ||
| Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. | Q48510719 | ||
| A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). | Q48682640 | ||
| SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine | Q48911278 | ||
| Differential neural reward mechanisms in treatment-responsive and treatment-resistant schizophrenia. | Q50032014 | ||
| Polygenic risk score prediction of antipsychotic dosage in schizophrenia. | Q50545760 | ||
| Correlation of functional GRIN2A gene promoter polymorphisms with schizophrenia and serum D-serine levels. | Q50586579 | ||
| Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. | Q50946700 | ||
| Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia. | Q51708824 | ||
| Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia | Q40562177 | ||
| Structural Abnormalities in the Cerebral Cortex of Chronic Schizophrenic Patients | Q40717475 | ||
| No progression of the alterations in the cortical thickness of individuals with schizophrenia-spectrum disorder: a three-year longitudinal magnetic resonance imaging study of first-episode patients | Q40906631 | ||
| Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia | Q41187586 | ||
| Abnormalities of Dopamine D3 Receptor Signaling in the Diseased Brain | Q41456216 | ||
| The pharmacogenetics of symptom response to antipsychotic drugs. | Q41500882 | ||
| ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine | Q41634218 | ||
| Magnetic resonance imaging and single photon emission tomography in treatment-responsive and treatment-resistant schizophrenia | Q41671450 | ||
| Functional connectivity as a means to delineate differences between treatment-resistant and treatment-responsive schizophrenia | Q41866829 | ||
| Recovery, not progressive deterioration, should be the expectation in schizophrenia | Q42026249 | ||
| D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis | Q42056580 | ||
| Brain connectivity changes occurring following cognitive behavioural therapy for psychosis predict long-term recovery. | Q42363334 | ||
| Psychosis breakthrough on antipsychotic maintenance medication (BAMM): what can we learn? | Q42374864 | ||
| Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics | Q43069118 | ||
| Serotonin transporter gene polymorphisms and treatment-resistant depression | Q43069858 | ||
| HTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients | Q43087574 | ||
| Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients | Q43183593 | ||
| Effect of clozapine on caudate nucleus volume in relation to symptoms of schizophrenia | Q43562521 | ||
| Prefrontal cortical sulcal widening associated with poor treatment response to clozapine | Q43570105 | ||
| Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene | Q43592699 | ||
| Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia | Q43864207 | ||
| Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene | Q44118973 | ||
| 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia | Q44231417 | ||
| Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia | Q44233166 | ||
| The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes | Q44538141 | ||
| The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development | Q44543027 | ||
| Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia | Q44658962 | ||
| Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function | Q44893993 | ||
| Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement | Q45057714 | ||
| Accelerated Brain Aging in Schizophrenia: A Longitudinal Pattern Recognition Study. | Q45952063 | ||
| Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. | Q45988460 | ||
| Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. | Q46002789 | ||
| Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. | Q46006540 | ||
| Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients | Q46114329 | ||
| Striatal metabolic rate and clinical response to neuroleptics in schizophrenia | Q46127995 | ||
| Correlates of response to Olanzapine in a North Indian Schizophrenia sample. | Q46253388 | ||
| Converging evidence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olanzapine treatment | Q46431487 | ||
| Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations | Q46437618 | ||
| Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients | Q46486910 | ||
| Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. | Q46507677 | ||
| Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes | Q46523452 | ||
| Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics | Q46542398 | ||
| Genetic association analysis of N-methyl-D-aspartate receptor subunit gene GRIN2B and clinical response to clozapine | Q46913948 | ||
| DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients | Q46973173 | ||
| Association of ABCB1 Gene Polymorphisms with Efficacy and Adverse Reaction to Risperidone or Paliperidone in Han Chinese Schizophrenic Patients | Q47133433 | ||
| Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients | Q47314418 | ||
| The Relationship Between Clinical and Personal Recovery in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-analysis. | Q47567149 | ||
| Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice | Q47618934 | ||
| GWAS analysis of treatment resistant schizophrenia: interaction effect of childhood trauma | Q47737250 | ||
| Functional network dysconnectivity as a biomarker of treatment resistance in schizophrenia | Q47774122 | ||
| Functional brain networks in treatment-resistant schizophrenia. | Q47844810 | ||
| Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down | Q48135229 | ||
| Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations. | Q48170412 | ||
| Progressive ventricular expansion in chronic poor-outcome schizophrenia | Q48171681 | ||
| Glutamate and schizophrenia: beyond the dopamine hypothesis | Q33996803 | ||
| Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia | Q34041815 | ||
| Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine | Q34048732 | ||
| Treatment refractory schizophrenia | Q34057141 | ||
| Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials | Q34205157 | ||
| Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. | Q34337272 | ||
| Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. | Q34351095 | ||
| Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia | Q34413325 | ||
| The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies | Q34468314 | ||
| DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia | Q34508840 | ||
| A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. | Q34568745 | ||
| The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. | Q34585605 | ||
| Schizophrenia susceptibility and NMDA-receptor mediated signalling: an association study involving 32 tagSNPs of DAO, DAOA, PPP3CC, and DTNBP1 genes | Q34623618 | ||
| From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment | Q34632695 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance | Q34640811 | ||
| Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk | Q34691699 | ||
| Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia | Q34807152 | ||
| Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related working memory behavior | Q34906834 | ||
| Meta-analysis of diffusion tensor imaging studies in schizophrenia | Q34917202 | ||
| White matter changes in schizophrenia: evidence for myelin-related dysfunction | Q35125866 | ||
| Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia | Q35417493 | ||
| Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia | Q35626964 | ||
| Physical Exercise Keeps the Brain Connected: Biking Increases White Matter Integrity in Patients With Schizophrenia and Healthy Controls | Q35739019 | ||
| Three dysconnectivity patterns in treatment-resistant schizophrenia patients and their unaffected siblings | Q35759100 | ||
| Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment | Q35960362 | ||
| Extensive gray matter volume reduction in treatment-resistant schizophrenia. | Q35965893 | ||
| Ionotropic and metabotropic glutamate receptor structure and pharmacology | Q36054635 | ||
| Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia | Q36234271 | ||
| Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. | Q36249164 | ||
| Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. | Q36300098 | ||
| Neuroimaging studies of cognitive remediation in schizophrenia: A systematic and critical review. | Q36344132 | ||
| Comprehensive analysis of schizophrenia-associated loci highlights ion channel pathways and biologically plausible candidate causal genes | Q36608885 | ||
| Dysfunctional Striatal Systems in Treatment-Resistant Schizophrenia. | Q36690658 | ||
| Cerebral morphometry and clozapine treatment in schizophrenia | Q36726965 | ||
| Clozapine response and the 5HT2C Cys23Ser polymorphism. | Q52007521 | ||
| Trajectories of subcortical volume change in schizophrenia: A 5-year follow-up. | Q52148414 | ||
| Potentially fatal outcomes associated with clozapine. | Q52675048 | ||
| Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study. | Q52675080 | ||
| Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and meta-regression analysis. | Q53080297 | ||
| Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive-compulsive symptoms. | Q53402728 | ||
| Addressing nonresponse in schizophrenia. | Q53648091 | ||
| Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard? | Q53748909 | ||
| Volume of the cingulate and outcome in schizophrenia. | Q53879058 | ||
| Synergistic association of PI4KA and GRM3 genetic polymorphisms with poor antipsychotic response in south Indian schizophrenia patients with low severity of illness. | Q54323354 | ||
| Therapeutic studies in "therapy resistant" schizophrenic patients. | Q54560908 | ||
| Biological Predictors of Clozapine Response: A Systematic Review | Q57174550 | ||
| Lack of progression of brain abnormalities in first-episode psychosis: a longitudinal magnetic resonance imaging study | Q57403293 | ||
| Pharmacogenetic prediction of clozapine response | Q57403405 | ||
| Genetic variation of 5-HT2A receptor and response to clozapine | Q57591723 | ||
| Longitudinal changes in brain structure following the first episode of psychosis | Q60242689 | ||
| Recovery from schizophrenia | Q60545970 | ||
| Schizophrenia as a progressive brain disease | Q60610023 | ||
| Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine | Q60628103 | ||
| Differential clinical, structural and P300 parameters in schizophrenia patients resistant to conventional neuroleptics | Q63387889 | ||
| Regional cortical anatomy and clozapine response in refractory schizophrenia | Q70800558 | ||
| Nuclear magnetic resonance in schizophrenia: a preliminary study | Q70954684 | ||
| Association between clozapine response and allelic variation in the 5-HT2C receptor gene | Q71351223 | ||
| Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine | Q72540541 | ||
| No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population | Q74642764 | ||
| Serotonin-6 receptor variant (C267T) and clinical response to clozapine | Q77861194 | ||
| Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia | Q81304560 | ||
| Time course for antipsychotic treatment response in first-episode schizophrenia | Q83058853 | ||
| Cognitive Behavioral Therapy Normalizes Functional Connectivity for Social Threat in Psychosis | Q36817163 | ||
| Qualitative cerebral morphology in schizophrenia: a magnetic resonance imaging study and systematic literature review. | Q36865916 | ||
| Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes | Q36915452 | ||
| HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis | Q36950578 | ||
| Glutamate and dopamine in schizophrenia: an update for the 21st century | Q36992322 | ||
| Variation in Dopamine D2 and Serotonin 5-HT2A Receptor Genes is Associated with Working Memory Processing and Response to Treatment with Antipsychotics | Q37024867 | ||
| Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects | Q37131066 | ||
| Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach | Q37170587 | ||
| Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response | Q37405204 | ||
| Altered interhemispheric and temporal lobe white matter microstructural organization in severe chronic schizophrenia | Q37584245 | ||
| Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials | Q37662441 | ||
| Pharmacogenetics of response to antipsychotics in patients with schizophrenia | Q37952823 | ||
| Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation | Q37994876 | ||
| The neuroanatomy of psychotic diathesis: a meta-analytic review. | Q38025880 | ||
| The pharmacogenetics of antipsychotic treatment. | Q38058015 | ||
| Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. | Q38062443 | ||
| Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia | Q38402758 | ||
| Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry | Q38626082 | ||
| Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis | Q38705086 | ||
| Brain-imaging studies of treatment-resistant schizophrenia: a systematic review | Q38762872 | ||
| The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia | Q38803633 | ||
| Treatment-Resistant Schizophrenia | Q38842564 | ||
| The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia | Q38863895 | ||
| DRD2 co-expression network and a related polygenic index predict imaging, behavioral and clinical phenotypes linked to schizophrenia | Q39017080 | ||
| Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology | Q39029626 | ||
| Connectomic correlates of response to treatment in first-episode psychosis. | Q39070362 | ||
| The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. | Q39269381 | ||
| Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. | Q39291255 | ||
| From Gene to Behavior: L-Type Calcium Channel Mechanisms Underlying Neuropsychiatric Symptoms | Q39301735 | ||
| Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness | Q39646600 | ||
| Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant | Q39916831 | ||
| The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis | Q40014174 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neuroimaging | Q551875 |
| precision medicine | Q17075943 | ||
| schizophrenia | Q41112 | ||
| P304 | page(s) | 402 | |
| P577 | publication date | 2019-04-16 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates | |
| P478 | volume | 10 |
Search more.